Welcome to LookChem.com Sign In|Join Free
  • or
methyl 3-(4-cyanobenzyloxy)benzoate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

169605-18-9

Post Buying Request

169605-18-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

169605-18-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 169605-18-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,9,6,0 and 5 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 169605-18:
(8*1)+(7*6)+(6*9)+(5*6)+(4*0)+(3*5)+(2*1)+(1*8)=159
159 % 10 = 9
So 169605-18-9 is a valid CAS Registry Number.

169605-18-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name methyl 3-(4-cyanobenzyloxy)benzoate

1.2 Other means of identification

Product number -
Other names 3-(4-Cyano-benzyloxy)-benzoic acid methyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:169605-18-9 SDS

169605-18-9Relevant academic research and scientific papers

Design, synthesis, and in vitro activities of benzamide-core glycoprotein IIb/IIIa antagonists: 2,3-Diaminopropionic acid derivatives as surrogates of aspartic acid

Xue, Chu-Biao,Roderick, John,Jackson, Sharon,Rafalski, Maria,Rockwell, Arlene,Mousa, Shaker,Olson, Richard E.,DeGrado, William F.

, p. 693 - 705 (1997)

In an effort to discover novel nonpeptide glycoprotein IIb/IIIa (GPIIb/IIa, α(IIb)/β3) inhibitors, we investigated RGD mimetics featuring a 3-substituted benzoic acid as the core, benzamidine as the basic moiety, and a series of β- and α-substituted β-alanine derivatives as aspartic acid surrogates. It was found that the use of β-methyl β-alanine slightly improved the anti-aggregant potency in human platelet-rich plasma over the unsubstituted β-alanine compound, while β-substitution with a trifluoromethyl group resulted in considerable loss in activity. Significant enhancement (up to 100-fold) in potency was obtained when the β-alanine was replaced with N2-substituted L-2,3-diaminopropionic acid derivatives. Among the three types of α-substituents (carbamate, amide, and sulfonamide) investigated, no apparent preference was observed with respect to in vitro potency. However, alkyl groups were more favorable than arylalkyl groups (Cbz) in the carbamate analogues. We also investigated piperidine, piperazine, and N-formamidinopiperidine as replacements for the benzamidine moiety. The former two replacements led to a drop in potency while the latter replacement resulted in maintenance of activity as compared with the corresponding benzamidine analogue.

Discovery of Potent, Selective, and Direct Acid Sphingomyelinase Inhibitors with Antidepressant Activity

Yang, Kan,Yu, Jinying,Nong, Keyi,Wang, Youzhi,Niu, Ao,Chen, Wenlu,Dong, Jibin,Wang, Jinxin

, p. 961 - 974 (2020/03/10)

Recent studies on sphingolipids suggest that acid sphingomyelinase (ASM), which plays a central role in the pathogenesis of major depression, is emerging to be a novel target for developing antidepressants. Herein we first described the design, synthesis,

Discovery of N-hydroxy-3-alkoxybenzamides as direct acid sphingomyelinase inhibitors using a ligand-based pharmacophore model

Yang, Kan,Nong, Keyi,Gu, Qinlan,Dong, Jibin,Wang, Jinxin

, p. 389 - 400 (2018/04/12)

Acid sphingomyelinase (ASM) has been shown to be involved in many physiological processes, emerging to be a promising drug target. In this study, we constructed a ligand-based pharmacophore model of ASM inhibitors and applied this model to optimize the lead compound α-mangostin, a known inhibitor of ASM. 23 compounds were designed and evaluated in vitro for ASM inhibition, of these, 10 compounds were found to be more potent than α-mangostin. This high hit ratio confirmed that the presented model is very effective and practical. The most potent hit, 1c, was found to selectively and competitively inhibit the enzyme and inhibit the generation of ceramide in a dose-dependent manner. Furthermore, 1c showed favorable anti-apoptosis and anti-inflammatory activity. Interactions with key residues and the Zn2+ cofactor of 1c were found by docking simulation. These results provide promising leads and important guidance for further development of efficient ASM inhibitors and drug candidates.

Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists

-

, (2008/06/13)

This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 169605-18-9